United Therapeutics Corp. (UTHR) PT Lowered to $400 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $400.00 (from $425.00) while maintaining a Buy rating.

The analyst commented: 'With top-line data from the TETON trial expected in September from the TETON 2 trial and the first half of 2026 from the TETON 1 trial, we spoke with KOLs to gather their perspectives on the study. Recall that United Therapeutics’ TETON trial, a study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF), arose from the surprising findings of the INCREASE trial of nebulized Tyvaso for the treatment of PH-ILD. With the recent approval of Yutrepia, we estimate a decrease in Tyvaso's penetration in both PAH and PH-ILD due to increased competition, we decrease our price target to $400 from $425 and we reiterate our Buy rating."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Full Circle Lithium closes $5.14M private placement
• Boeing lands two U.S. defense contracts worth over $711M